The press release published on May 21, 2025, by the U.S. Food and Drug Administration (FDA) announces new measures aimed at improving state prescription drug importation programs.

These actions are part of the implementation of a federal Executive Order aimed at reducing high drug prices in the country, prioritizing the well-being of American citizens.

The FDA emphasizes that drug prices in the United States can be five to ten times higher than in other developed nations, such as European countries. In response to this situation, the agency seeks to make it easier for states and Indigenous tribes to import certain prescription drugs from Canada. This measure is implemented under Section 804 of the Federal Food, Drug, and Cosmetic Act, which allows this type of importation as long as the safety and efficacy of the products are guaranteed, without posing additional risks to public health.

WHOM DOES THIS IMPACT?

The direct impact is on American patients, state governments, public and private healthcare systems, and the domestic pharmaceutical industry.

CONCLUSION:

The FDA's actions have a significant impact because they address a structural problem that affects millions of people, promote concrete, federally supported solutions, and could change both access to and the market for medicines in the United States.